The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II investigator-initiated study of olaparib and temozolomide in SCLC: Updated analysis and CNS outcomes.
 
Catherine Belle Meador
No Relationships to Disclose
 
Subba Digumarthy
Honoraria - Siemens
Travel, Accommodations, Expenses - Siemens Healthcare Diagnostics; Siemens Healthcare Diagnostics
Other Relationship - Provides independent image analysis for hospital contracted clinical research trials programs for several companies including Merck, Pfizer, Bristol Mayer Squibb, Novartis, Roche, Polaris, Cascadian, Abbvie, Gradalis, Clinical Bay, Zai laboratories. R (Inst)
 
Beow Y. Yeap
Research Funding - Taiho Pharmaceutical
 
Anna F. Farago
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Consulting or Advisory Role - AstraZeneca; Bayer
 
Rebecca Suk Heist
Honoraria - Chugai/Roche
Consulting or Advisory Role - Abbvie; Daichii Sankyo; Daichii Sankyo; EMD Serono/Merck; EMD Serono/Merck; Novartis
Research Funding - Abbvie (Inst); Agios (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Exelixis (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
 
J Paul Marcoux
No Relationships to Disclose
 
Deepa Rangachari
Honoraria - AstraZeneca
Consulting or Advisory Role - Advance Medical; DynaMed
Research Funding - Abbvie/Stemcentrx (Inst); Bristol-Myers Squibb (Inst); Novocure (Inst)
 
David Allen Barbie
Employment - N-of-One
Stock and Other Ownership Interests - N-of-One; Xsphera Biosciences
Honoraria - Abbvie; Eisai/H3 Biomedicine; EMD Serono/Merck; Merck
Consulting or Advisory Role - Dantari; N-of-One; Tango Therapeutics
Research Funding - Bristol-Myers Squibb; Gilead Sciences; Lilly; Novartis
Patents, Royalties, Other Intellectual Property - DFCI patents on microfluidic culture and analysis of organotypic tumor spheroids
 
Zofia Piotrowska
Consulting or Advisory Role - Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo Europe GmbH; Janssen; Jazz Pharmaceuticals; Takeda
Research Funding - Abbvie (Inst); ARIAD/Takeda (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline/Tesaro (Inst); Janssen Oncology (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune